Evidence map›Paper›PMID 26629338›Full record

ArticleCancer & metabolism2015

Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells.

Susan J Gelman, Nathaniel G Mahieu, Kevin Cho, Elizabeth M Llufrio, Timothy A Wencewicz, Gary J Patti

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Susan J GelmanDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
Nathaniel G MahieuDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
Kevin ChoDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
Elizabeth M LlufrioDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
Timothy A WencewiczDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA.
Gary J PattiDepartment of Chemistry, Washington University, St. Louis, MO 63130 USA ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
Washington University in St. Louis · US

Funding

DEVELOPING THE UNTARGETED METABOLOMIC WORKFLOW FOR HIGH-THROUGHPUT ANALYSESR01ES022181 · NIEHS · WASHINGTON UNIVERSITY · PI PATTI, GARY J · 2012 to 2016
$1.8M
NIA NIH HHS L30 AG038036NIEHS NIH HHS R01 ES022181
6 · The paper itself

Abstract

backgroundTwo-hydroxyglutarate (2HG) is present at low concentrations in healthy mammalian cells as both an L and D enantiomer. Both the L and D enantiomers have been implicated in regulating cellular physiology by mechanisms that are only partially characterized. In multiple human cancers, the D enantiomer accumulates due to gain-of-function mutations in the enzyme isocitrate dehydrogenase (IDH) and has been hypothesized to drive malignancy through mechanisms that remain incompletely understood. While much attention has been dedicated to identifying the route of 2HG synthesis, the metabolic fate of 2HG has not been studied in detail. Yet the metabolism of 2HG may have important mechanistic consequences influencing cell function and cancer pathogenesis, such as modulating redox potential or producing unknown products with unique modes of action.

resultsBy applying our isotope-based metabolomic platform, we unbiasedly and comprehensively screened for products of L- and D-2HG in HCT116 colorectal carcinoma cells harboring a mutation in IDH1. After incubating HCT116 cells in uniformly (13)C-labeled 2HG for 24 h, we used liquid chromatography/mass spectrometry to track the labeled carbons in small molecules. Strikingly, we did not identify any products of 2HG metabolism from the thousands of metabolomic features that we screened. Consistent with these results, we did not detect any significant changes in the labeling patterns of tricarboxylic acid cycle metabolites from wild type or IDH1 mutant cells cultured in (13)C-labeled glucose upon the addition of L, D, or racemic mixtures of 2HG. A more sensitive, targeted analysis revealed trace levels of isotopic enrichment (<1 %) in some central carbon metabolites from (13)C-labeled 2HG. However, we found that cells do not deplete 2HG from the media at levels above our detection limit over a 48 h time period.

conclusionsTaken together, we conclude that 2HG carbon is not readily transformed in the HCT116 cell line. These data indicate that the phenotypic alterations induced by 2HG are not a result of its metabolic products.

Indexed as

13C-tracing2-HydroxyglutarateCancer metabolismIsotope-based metabolomicsMass spectrometryMetabolomics

Identifiers

PMID26629338
PMCPMC4665876
OpenAlexW2183713362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.